That's not 82% of bladder cancers.

It's 82% of those whose bladder cancer is fortunately not invading the muscle, and after failing current standard treatments.

As I noted elsewhere in the thread:

(1) For this trial, patients with MIBC (as opposed to NMIBC) weren't in the cohort, so we don't know what the results will be with MIBC.

(2) "After failing current standard treatments" makes the result more impressive, not less.